Bicara gains buy rating as BofA sees SoC potential in cancer drug Ficera.
Share this article
Corporate
Score 65
Bullish
Bicara gains buy rating as BofA sees SoC potential in cancer drug Ficera
Mar 25, 2026 18:50 UTC
BICR, XLV, IHX
Short term
Related Articles
Score 85
Bullish
Brown-Forman’s stock soared on deal talks. Its valuation had tumbled to financial-crisis levels.
Mar 27, 08:09
Score 65
Helium Shortage Sparks Widespread Concerns Beyond Birthday Parties
Mar 27, 08:00
Score 45
Bullish
Santander’s Botin Sees Efficiency Improving in First Quarter
Mar 27, 07:11
Score 85
Bullish
AI Breakthrough From Google Exposes Divide in Memory Chip Stocks
Mar 27, 05:59
Stay Ahead of the Markets
Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.